June 26 - 27, 2006
William and Ida Friday Center for Continuing Education
Chapel Hill, North Carolina
Jointly sponsored by The School of Medicine of The University of North Carolina at Chapel Hill, The Lustgarten Foundation for Pancreatic Cancer Research, and the American Association for Cancer Research
Joel E. Tepper, University of North Carolina, Chapel Hill, NC
There is an increasing body of information being developed regarding the early diagnosis and treatment of pancreatic cancer. As more is learned of the biology of the disease, the options for defining patients at high risk of developing pancreatic cancer, and developing means of detecting those tumors at an early stage, increases dramatically. In addition, the increasing knowledge of the biology of the tumor opens multiple potential therapeutic options, by directing treatment at these new biologic targets.
This meeting was designed to bring together basic scientists and clinicians to deal with the two issues of early detection and novel therapeutics. The first part of the meeting addressed the definition of high risk patients and how those patients should be evaluated. New therapeutic options were addressed by basic scientists with an understanding of the underlying biology of the disease as well as by clinically oriented investigators who discussed how to bring these potential therapies into clinical implementation. These were supplemented by poster sessions on new advances.
*(Adobe Acrobat Reader required)
Please visit the AACR Meeting Calendar for a complete list of upcoming programs.